PIPELINE
Scaling new heights in early disease interception
Early cancer
screening
GASTROClear Test
The world's first RNA blood test for early detection of gastric cancer
Infectious, cardiovascular, and metabolic diseases
Fortitude Kit
A SARS-CoV-2 RT-PCR test for accurate testing of COVID-19
Discovery and
development
ID3EAL Suite
Versatile market-leading microRNA research solutions for scientists
In the pipeline:
detection:
Gastric Cancer
Lung Cancer
Breast Cancer
Colorectal Cancer
Ovarian Cancer
Liver Cancer
In the pipeline:
test for
infectious disease.
metabolic diseases
COVID-19
Heart Failure
Pulmonary Hypertension
Sepsis
Insulin Resistance
In the pipeline:
new ID3EAL microRNA knowledge panel.
Cancer microRNA Panel
Biofluid microRNA Panel
PanoramiR Disease Relevant Panel
Viral microRNA Panel
Early cancer
screening
GASTROClear Test
The world's first RNA blood test for early detection of gastric cancer
In the pipeline:
detection:
Gastric Cancer
Lung Cancer
Breast Cancer
Colorectal Cancer
Ovarian Cancer
Liver Cancer
Infectious, cardiovascular, and metabolic diseases
Fortitude Kit
A SARS-CoV-2 RT-PCR test for accurate testing of COVID-19
In the pipeline:
test for
infectious disease.
metabolic diseases
COVID-19
Heart Failure
Pulmonary Hypertension
Sepsis
Insulin Resistance
Early cancer
screening
ID3EAL Suite
Versatile market-leading microRNA research solutions for scientists
In the pipeline:
new ID3EAL microRNA knowledge panel.
Cancer microRNA Panel
Biofluid microRNA Panel
PanoramiR Disease Relevant Panel
Viral microRNA Panel
Read more about our latest and key scientific publications here.
24 Mar 2021
Mammography is extensively used for breast cancer screening but has high false-positive rates. This paper describes the discovery, development, and validation of a serum 6-miRNA panel to discriminate between malignant and benign breast lesions among women with abnormal mammograms.
24 Feb 2021
Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.
24 Feb 2021
Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.
24 Feb 2021
Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.
24 Feb 2021
Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.
24 Feb 2021
Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.
SOCIAL MEDIA
